Research

Urologic Research at the University of Chicago

 

The Section of Urology at the University of Chicago has a strong legacy and rich tradition of clinical research in urologic oncology. Our objectives are to improve the treatment of patients with cancer. Our focus is on the patients and how we, as scientists, can improve their lives.

 

New Cancer Therapy Program
The Program in New Cancer Therapies was created to consolidate clinical and laboratory research efforts in improving the management of patients with urologic cancers. The primary objective is to develop, advance, and subsequently offer state-of-the-art treatments to patients with urologic cancers by developing improved therapies and treatment paradigms that incorporate novel anti-cancer agents and technologies as a compliment to conventional surgical therapy.

 

Our endeavors are based on the following three principles:

  • Combining conventional surgical therapies with both standard and experimental adjuvant treatments.
  • Embracing minimally-invasive technologies and expanding their role in patient care.
  • Advocating investigator-initiated clinical trials designed in the true spirit of translational research, in which laboratory discoveries are applied to patient management and observations from the clinic are explored at the bench. Correlative scientific investigation will aid in improved understanding of molecular, genetic, and biochemical pathophysiologic processes of these cancers and in the creation of better management strategies.


Clinical Trials
New drugs and treatments are often evaluated through a series of studies called clinical trials. These are closely monitored and regulated studies in which the effectiveness and safety of new drugs and technologies are evaluated.
Clinical trials consist of three phases. The purpose of phase 1 is to determine possible side effects of a drug or treatment method. If results from phase 1 trials are positive, the drug is tested in a larger group of patients to determine how it affects a specific disease and what its short-term side effects may be. Phase 2 studies focus on comparing the new treatment with the current treatment or placebo. In phase 3 clinical trials, the drug is further studied for safety and efficacy in a much larger group of patients who have the disease being studied.

 

If you want to learn more about the trials underway or planned or to make an appointment, we invite you to call the Section of Urology at (773)702-0792.

 

Accruing Clinical Trials Investigator IRB Number
Phase III, Multicenter Study of the Efficacy and Safety of MCC in the Treatment of Patients with Non-Muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression, Refractory to BCG
 		 Dr. Steinberg 15216A
A Multicenter, Randomized , Placebo-Controlled, Double-Blind Phase III Trial of Single-Dose Intravesical Apaziquone as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer Dr. Steinberg 15448B
A Phase II , Randomized, Double-Blind, Multi-Centered Study of Green Tea Capsules in Men with High Grade Prostate Intraepithelial Neoplasia (HGPIN)
 		 Dr. Zagaja 15980B
 
Clinical Urology Research Screening Protocol Dr. Shalhav 12278A
Quality of Life After Radical Prostatectomy Dr. Zagaja 12803B
Bladder Cancer Sample Collection Dr. Steinberg 15550B
Normal Subject Urine Sample Collection Dr. Steinberg 15594B
Sexual Function After a Robotic Assisted Laparoscopic Prostatectomy: Effect of Race on Recovery Outcomes Dr. Zorn 15850B
Quality of Life After Cystectomy Dr. Steinberg 15871A
Sexual Satisfaction of Women with Pelvic Organ Prolapse and Their Male Partners Dr. Bales 15909B
Factors Affecting Post-Cystectomy Delirium in Older Patients: A Pilot Study Dr. Bales 16238B
Ureter Tissue Collection Dr. Shalhav 16305B
Randomized, Multi-Institutional Trial of Ciprofloxacin versus Observation for Men with an Elevated Prostate Specific Antigen (PSA) Dr. Eggener 16368B
Phase III, Multi-Institutional Randomized Clinical Trial: Effect of Type of Ischemia-Warm vs. Cold During Partial Nephrectomy--On Renal Function Dr. Eggener 16556B